A recent publication in Cell Reports adds to the emerging consensus that metformin acts on the gut and kidneys to increase circulating levels of growth differentiation factor 15 (GDF15). However, the report also highlights circumstances in which the effects of metformin on body weight and energy balance seem to be independent of GDF15–GFRAL signalling.
This is a preview of subscription content, access via your institution
Access options
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
$29.99
monthly
Subscribe to Journal
Get full journal access for 1 year
$79.00
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
Lachin, J. M. et al. Factors associated with diabetes onset during metformin versus placebo therapy in the Diabetes Prevention Program. Diabetes 56, 1153–1159 (2007).
Gerstein, H. C. et al. Growth differentiation factor 15 as a novel biomarker for metformin. Diabetes Care 40, 280–283 (2016).
Coll, A. P. et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature 578, 444–448 (2020).
Day, E. A. et al. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat. Metab. 1, 1202–1208 (2019).
Klein, A. B. et al. The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance. Cell Rep. 40, 111258 (2022).
de Meijer, V. E., Le, H. D., Meisel, J. A. & Puder, M. Repetitive orogastric gavage affects the phenotype of diet-induced obese mice. Physiol. Behav. 100, 387–393 (2010).
Carreras-Badosa, G. et al. A 24-month metformin treatment study of children with obesity: Changes in circulating GDF-15 and associations with changes in body weight and visceral fat. Pediatr. Obes. 17, e12845 (2022).
Lu, J. F. et al. Camptothecin effectively treats obesity in mice through GDF15 induction. PLOS Biol. 20, e3001517 (2022).
Zhang, S.-Y., Li, R. J. W., Danaei, Z., Lim, Y. & Lam, T. K. 154-OR: The site-specific role of GDF15 in metformin action. Diabetes 71, 154 (2022). -OR.
Pénicaud, L., Hitier, Y., Ferré, P. & Girard, J. Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem. J. 262, 881–885 (1989).
Acknowledgements
The authors gratefully acknowledge Professor Sir Stephen O’Rahilly (University of Cambridge) for helpful discussions in the preparation of this manuscript. A.P.C. acknowledges the support of the UK Medical Research Council (MRC) Metabolic Diseases Unit (MC_UU_00014/1).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Kincaid, J.W.R., Coll, A.P. Metformin and GDF15: where are we now?. Nat Rev Endocrinol 19, 6–7 (2023). https://doi.org/10.1038/s41574-022-00764-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-022-00764-6